Tripep AB (publ)-Interim Report, January - June 2004

Tripep AB (publ)-Interim Report, January - June 2004 ·Loss after tax SEK -13.9 million (SEK -11.9 m). Research and development costs were SEK 6.9 million (SEK 6.6 m). The company has yet to generate operating income, and thereby, has no net sales. Earnings per share: SEK -1.11 (SEK -0.88). ·Tripep´s new anti-HIV drug alphaHGA has now entered its clinical phase development after completing a microdosing study on humans, performed with the aid of what is termed acceleration mass spectrometry. The results demonstrate that this drug is well absorbed into the blood from the digestive tract after oral administration. The terminal half-life in plasma was 10 hours. ·A doctoral thesis was presented at the Karolinska Institutet, Sweden, in the period describing the development of ChronVac-CTM. ·Anders Vahlne replaced Johan Ihre as CEO as of 1 July 2004. For more information, please contact Anders Vahlne, Chief Executive Officer & Head of Research Tel: +46 (0)8 585 81313, mobile: +46 (0)70 928 0528 E-Mail: anders.vahlne@labmed.ki.se Tripep is a biotech research company that develops and commercialises candidate drugs based on patented technologies: -clinical development of a HIV-inhibiting drug, -preclinical research focusing on the development of therapeutic and prophylactic vaccines against HIV and hepatitis C, -the RAS® and Ribacine technology platforms, and -a general influenza vaccine in a joint participation with VLP Biotech Inc. More details on Tripep's technologies are available at its Website: www.tripep.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/08/27/20040827BIT20240/wkr0001.pdf The Full Report http://www.waymaker.net/bitonline/2004/08/27/20040827BIT20240/wkr0003.doc